New anxiety drug shows promise in early brain study
NCT ID NCT07478744
First seen Mar 25, 2026 · Last updated Jun 18, 2026 · Updated 19 times
Summary
This study tests whether a single dose of the experimental drug SYT-510 can reduce anxiety-related brain activity and behavior in 24 adults with generalized anxiety disorder. Participants will receive either the drug or a placebo, then switch after a washout period. The goal is to see if SYT-510 affects brain scans and defensive responses, helping design future trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED ANXIETY DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SLaM
RECRUITINGLondon, United Kingdom
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.